Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment
This study highlights that a substantial number of patients with localized CRC undergoing curative-intent treatment with CAPOX do not complete the planned cycles of chemotherapy because of toxicity. These findings underscore the need for careful patient selection and appropriate supportive care to optimize the therapeutic benefit of CAPOX in this setting.
Authors
- Amit Mahipal (ORCID: https://orcid.org/0000-0002-1111-8333)
- Madison Conces (ORCID: https://orcid.org/0000-0003-1505-0521)
- Veronica Mears (ORCID: https://orcid.org/0000-0002-1229-9551)
- Melissa Lumish (ORCID: https://orcid.org/0000-0003-4173-5567)
- J. Eva Selfridge (ORCID: https://orcid.org/0000-0001-8979-1416)
- David J. Bajor
- Nikolas Naleid (ORCID: https://orcid.org/0009-0005-3297-1041)
- Sakti Chakrabarti (ORCID: https://orcid.org/0000-0002-1582-098X)
- Omkar Pawar (ORCID: https://orcid.org/0009-0006-1086-0911)
Institutions
- University Hospitals of Cleveland (US)
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1200/op-24-00647
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05